Mark Basile and his staff certainly do know how to author a shareholder letter for an OTC company. You didn't actually come right out and say it the other day -- but I will >> Dennis isn't smart enough to put that together.
"Legacy holders?" See the 3-year chart. A legacy holder would have to have mismanaged the position pretty miserably to be worried about recovering losses. This company went from the speculative value of its patents to a NASDAQ listed growth company in less than three years. Legacy holders do not need a "translation."
Market Data 
Markets 
AI
